Asia–Pacific Contract Manufacturing Market, By Product (Pharmaceutical Products Manufacturing and Medical Device Manufacturing), By End User (Pharmaceutical Companies, Biotechnology Companies, Biopharma Companies, Medical Device Companies, Original Equipment Manufacturer, and Research Institutes), By Distribution Channel (Retail Sales, Direct Tender, and Others) - Industry Trends and Forecast to 2030.
Asia–Pacific Contract Manufacturing Market Analysis and Insights
Asia-Pacific contract manufacturing market is driven by the factors such as rising technical advancements and cost effectiveness of pharmaceutical and pipeline products enhances its demand as well as rising investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.
Contract manufacturing is a contract between a company and a manufacturer to make a certain number of components or products for the company in a specified period of time. The goods created will be under the company’s label or brand. This is called private label manufacturing. This is often also called outsourcing if it is done across borders. Manufacturers provide their service based on their own designs, formulas, and specifications unless the customer provides its own. They will create these products to whomever they have contracted with, even competing firms.
One of the primary factors driving the growth of the contract manufacturing market is the rising demand in medical device & pharmaceutical sector Asia-Pacificly. The continuing clinical trial research being conducted by several companies for better diagnosis leads to market expansion. The market is also influenced by the rising technological advancements and cost effectiveness. However, the risk of confidential information and stringent regulations may act as restraining factors for the Asia-Pacific Contract Manufacturing Market in the forecast period
On the other hand, patent expiry and increasing demand for generic drugs, growing expenses in healthcare infrastructure and strategic initiatives by key market players act as an opportunity for the growth of the market. However, the intellectual property risk and increasing number of pharmaceutical companies to set up their own manufacturing units may create challenges for the Asia-Pacific Contract Manufacturing Market.
The demand for contract manufacturing will increase Asia-Pacificly due to an increasing inclination toward point-of-care diagnostics. Various companies are taking initiatives that gradually lead to the growth of the market.
The Asia-Pacific contract manufacturing market is supportive and aims to reduce the manufacturing efforts of healthcare organizations. Data Bridge Market Research analyses that the Asia-Pacific contract manufacturing market will grow at a CAGR of 5.8% during the forecast period of 2023 to 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product (Pharmaceutical Products Manufacturing and Medical Device Manufacturing), By End User (Pharmaceutical Companies, Biotechnology Companies, Biopharma Companies, Medical Device Companies, Original Equipment Manufacturer, and Research Institutes), By Distribution Channel (Retail Sales, Direct Tender, and Others)
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific
|
|
Market Players Covered
|
Aenova Group, Thermo Fisher Scientific Inc., EVONIK INDUSTRIES AG, Lonza, Boehringer Ingelheim Biopharmaceuticals GmbH., and Catalent, Inc among others
|
Asia-Pacific Contract Manufacturing Dynamics
Market Definition
Contract manufacturing in international markets is used in situations when one company arranges for another company in a different country to manufacture its products; this is also known as international subcontracting or international outsourcing. The company provides the manufacturer with all the specifications, and, if applicable, also with the materials required for the production process. This type of contract sets out the requirements, which the manufacturer must meet concerning the quality of the products, certification, quantities, conditions and dates of delivery, etc. It also establishes guidelines for the inspection and testing of the products set forth by the company which contracts out the manufacture, or by its own clients. Furthermore, it also outlines modifications to orders, as well as guarantees and compensation in case of breach of contract. Since the process is essentially outsourcing production in foreign markets to a partner that privately brands the end product, there are a number of different companies and industries that can make use of this type of contract.
Drivers
- Cost-effectiveness for the manufacturing companies
The time-consuming manufacturing and ineffective production for several things and management are major burdens for public and private sector organizations. They are also essential for addressing complex challenges because a single organization is less effective in driving the change and sometimes required outcomes. The contract manufacturing companies will act as rising opportunities for both governmental and private sectors
The rising demand for contract manufacturing with improved accuracy and less time constraint pushes the key players for strategic initiatives. Owning contract manufacturing frees up the overhead charges required to invest in machinery, material, and another workforce, simplifying the production process and streamlining the supply chain by reducing the overall cost.
However, major market players are investing heavy capital in manufacturing to reach the demands of their end users. The contract manufacturing players are involved in making the strategies and implementing them by reducing the cost of production of these players. Contract manufacturing services to other firms also ensure efficiency and optimum usage of resources by using effective workforce, strategic intelligence, or working resources required in the production cycle.
- Rise of technological advancements in contract manufacturing
Introducing a new drug in the market promptly requires considerable investments in manufacturing due to the escalated demand in the pharmaceutical industry. Advanced technologies and skills are mandatory as some drugs have complex formulas and require specific equipment and techniques when mass-produced.
The usage of innovative technologies such as machine learning, big data, and artificial intelligence to develop pharmaceutical drugs or manufacture medical devices are being considered for rapid and quick manufacturing. These technical advancements also help in mass production and scalability in a short span of time.
However, pharmaceutical firms conventionally audit or supervise their contract manufacturing organization's production and delivery processes to monitor the manufacturing process using real-time remote tracing.
Opportunities
- Growing expenses on the development of healthcare infrastructure
Infrastructure is a key pillar supporting the fundamental aim of promoting improved standards of care and well-being for all patients, together with a good healthcare system experience. In parallel, the healthcare system and staff must support effective health promotion, prevention, and self-care of the whole population. Infrastructure must integrate the hospital, as the center for acute and inpatient care, into the broader healthcare system and should facilitate the seven domains of quality patient experience, effectiveness, efficiency, timeliness, safety, equity, and sustainability. Infrastructure includes the built environment and supporting elements: equipment, access, information technology (IT), systems and processes, sustainability initiatives, and staff.
However, the growing expenses on the development of healthcare infrastructure are propelling the growth of the Asia-Pacific contract manufacturing market in the forecast period.
Restraints/Challenges
- Increase in the Number of Pharmaceutical Companies Set Up Their Manufacturing Sites
Most pharmaceutical companies are building manufacturing sites to produce pharmaceutical products to reduce costs. Manufacturers are more focused on introducing advanced technologies and the digitalization process. The Pharma industry also faces disruptions due to new business models and a more focused population on personalized medicines and treatments. Hence, the demand for personalized care is high. Occupational profiles are also changing: some jobs are disappearing due to automation while entirely new jobs are emerging.
Hence, the increasing number of pharmaceutical companies setting up their manufacturing units may challenge the growth of the Asia-Pacific contract manufacturing market in the forecast period.
Recent Developments
- In October 2021, Boehringer Ingelheim International gmbh., had inaugurated its state-of-the-art biopharmaceutical production facility Large Scale Cell Culture (LSCC) in Vienna, Austria, with an investment volume of more than 700 million EUR, which is the single largest investment in the company's history
- In March 2023, Evonik Industries AG has announced that it is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and provides customers with quantities of lipids as needed for clinical and small-scale commercial manufacturing
Asia-Pacific Contract Manufacturing Market Segmentation
The Asia-Pacific contract manufacturing market is categorized into three notable segments based on product, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product
- Medical Device Manufacturing
- Pharmaceutical Products Manufacturing
On the basis of product, the Asia-Pacific contract manufacturing market is segmented into medical device manufacturing and pharmaceutical products manufacturing.
End User
- Pharmaceutical Companies
- Biotechnology Companies
- Biopharma Companies
- Medical Device Companies
- Original Equipment Manufacturer
- Research Institutes
On the basis of end user, the Asia-Pacific contract manufacturing market is segmented into original equipment manufacturer, medical device companies, pharmaceutical companies, biotechnology companies, biopharma companies, and research institutes.
Distribution Channel
- Retail Sales
- Direct Tender
- Others
On the basis of distribution channel, the Asia-Pacific contract manufacturing market is segmented into direct tenders, retail sales, and others.
Asia-Pacific Contract Manufacturing Market Regional Analysis/Insights
The Asia-Pacific contract manufacturing market is analyzed, and market size insights and trends are provided by product, end user, and distribution channel as referenced above.
Some countries covered in the contract manufacturing report are Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
Japan is expected to dominate due to increasing technological advancement in developing areas.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Contract Manufacturing Market Share Analysis
Asia-Pacific contract manufacturing market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Asia-Pacific contract manufacturing market.
Some players in the market are Aenova Group, Thermo Fisher Scientific Inc., EVONIK INDUSTRIES AG, Lonza, Boehringer Ingelheim Biopharmaceuticals GmbH. and Catalent, Inc among others.
SKU-